Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant in Advanced ER-Positive Uterine Sarcomas
NCT07467772Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in uterine sarcoma, sponsored by Dana-Farber Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
elacestrant
03
Conditions
uterine sarcoma
Beyond the preview
Go deeper on NCT07467772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467772.